WO2006097732A3 - Treatment of autoimmune and inflammatory diseases - Google Patents

Treatment of autoimmune and inflammatory diseases Download PDF

Info

Publication number
WO2006097732A3
WO2006097732A3 PCT/GB2006/000945 GB2006000945W WO2006097732A3 WO 2006097732 A3 WO2006097732 A3 WO 2006097732A3 GB 2006000945 W GB2006000945 W GB 2006000945W WO 2006097732 A3 WO2006097732 A3 WO 2006097732A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoimmune
treatment
inflammatory diseases
polypeptides
isolated
Prior art date
Application number
PCT/GB2006/000945
Other languages
French (fr)
Other versions
WO2006097732A2 (en
Inventor
Andreas Sjoeberg
Anna Blom
Dick Heinegard
Original Assignee
Anamar Medical Ab
Webber Philip Michael
Andreas Sjoeberg
Anna Blom
Dick Heinegard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anamar Medical Ab, Webber Philip Michael, Andreas Sjoeberg, Anna Blom, Dick Heinegard filed Critical Anamar Medical Ab
Publication of WO2006097732A2 publication Critical patent/WO2006097732A2/en
Publication of WO2006097732A3 publication Critical patent/WO2006097732A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to isolated polypeptides which are capable of inhibiting the activation of the complement system and the use of such polypeptides for the treatment of autoimmune and/or inflammatory diseases such as rheumatoid arthritis, osteoarthritis, atherosclerosis, respiratory distress syndrome, obstructive lung disease, glomerulonephritis, ischemia/reperfusion injury or multiple sclerosis. Preferably, the isolated peptides are fragments of fibromodulin.
PCT/GB2006/000945 2005-03-18 2006-03-16 Treatment of autoimmune and inflammatory diseases WO2006097732A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0505641.1 2005-03-18
GB0505641A GB0505641D0 (en) 2005-03-18 2005-03-18 Treatment of autoimmune and inflamatory diseases

Publications (2)

Publication Number Publication Date
WO2006097732A2 WO2006097732A2 (en) 2006-09-21
WO2006097732A3 true WO2006097732A3 (en) 2006-12-21

Family

ID=34531511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000945 WO2006097732A2 (en) 2005-03-18 2006-03-16 Treatment of autoimmune and inflammatory diseases

Country Status (2)

Country Link
GB (1) GB0505641D0 (en)
WO (1) WO2006097732A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
CN113087773B (en) * 2021-04-29 2022-02-18 安徽国肽生物科技有限公司 Yak bone peptide with blood sugar reducing and antioxidant functions and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099784A2 (en) * 2003-05-06 2004-11-18 Anamar Medical Ab Method for determining a tissue degradation process by detection of fibromodulin neoepitopes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099784A2 (en) * 2003-05-06 2004-11-18 Anamar Medical Ab Method for determining a tissue degradation process by detection of fibromodulin neoepitopes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEATHFIELD T F ET AL: "Cleavage of fibromodulin in cartilage explants involves removal of the N-terminal tyrosine sulfate-rich region by proteolysis at a site that is sensitive to matrix metalloproteinase-13", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 8, 20 February 2004 (2004-02-20), pages 6286 - 6295, XP002300001, ISSN: 0021-9258 *
ROOS A ET AL: "SPECIFIC INHIBITION OF THE CLASSICAL COMPLEMENT PATHWAY BY C1Q-BINDING PEPTIDES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 167, no. 12, 15 December 2001 (2001-12-15), pages 7052 - 7059, XP001056046, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
GB0505641D0 (en) 2005-04-27
WO2006097732A2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
WO2009043889A3 (en) Oxadiazole derivatives
WO2007106690A8 (en) Degenerate nucleobase analogs
WO2009008719A3 (en) Treatment and prevention of inflammatory diseases and autoimmune diseases
WO2007076055A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
EP2336174A3 (en) Human monoclonal antibodies against Hendra and Nipah viruses
WO2005023825A3 (en) Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
IL232501A (en) Proteinase-resistant analogs of peptide or polypeptide and uses thereof
WO2006109312A3 (en) Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2015027259A3 (en) Polypeptide for the hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof, and additive containing polypeptide, use of said polypeptide and method
TW200740844A (en) Novel MAdCAM antibodies
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2007052023A3 (en) Novel compounds
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2007061677A3 (en) Spirolactam aryl cgrp receptor antagonists
WO2007105111A3 (en) Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
WO2011084685A3 (en) Saposin-a derived peptides and uses thereof
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel
WO2009030498A3 (en) Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission
WO2009074552A3 (en) Multi-zone films
EP2039367A4 (en) Prophylactic/therapeutic agent for neurodegenerative disease
GB0525164D0 (en) Compounds
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
JOP20220055A1 (en) Therapeutic fusion proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06710107

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6710107

Country of ref document: EP